

1 **Identification of a *de novo* mutation in *TLK1* associated with a neurodevelopmental**
2 **disorder and immunodeficiency**

3
4 Marina Villamor-Payà^{1,2}, María Sanchiz-Calvo^{1,#}, Jordann Smak², Lynn Pais^{3,4}, Malika Sud⁴,
5 Uma Shankavaram², Alysia Kern Lovgren⁴, Christina Austin-Tse⁴, , Vijay S Ganesh^{4,5}, Marina
6 Gay¹, Marta Vilaseca¹, Gianluca Arauz-Garofalo¹, Lluís Palenzuela¹, Grace VanNoy^{3,4}, Anne
7 O'Donnell-Luria^{3,4} and Travis H. Stracker^{1,2}.

8
9
10

11 **Affiliations**

12 ¹Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and
13 Technology, Barcelona 08028, Spain

14 ²National Cancer Institute, Center for Cancer Research, Radiation Oncology Branch, Bethesda,
15 MD 20892, USA.

16 ³Division of Genetics & Genomics, Department of Pediatrics, Boston Children's Hospital,
17 Boston, MA 02115, USA.

18 ⁴Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge,
19 MA 02142, USA.

20 ⁵Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.

21 #Current affiliation: Laboratory for Neurobiology and Gene Therapy, Department of
22 Neurosciences, Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium

23
24 *Lead Contact: travis.stracker@nih.gov

25
26
27 Running title: *TLK1*-associated neurodevelopmental disorder

28
29 Keywords: Neurodevelopmental disorder, microcephaly, immunodeficiency, *TLK1*, *TLK2*,
30 *STAT3*

31
32
33
34
35
36
37
38
39
40
41
42

43

44 **Abstract**

45 **Background**

46 The Tousled-like kinases 1 and 2 (TLK1/TLK2) regulate DNA replication, repair and chromatin
47 maintenance. TLK2 variants are associated with 'Intellectual Disability, Autosomal Dominant 57'
48 (MRD57), a neurodevelopmental disorder (NDD) characterized by intellectual disability (ID),
49 autism spectrum disorder (ASD) and microcephaly. Several TLK1 variants have been reported
50 in NDDs but their functional significance is unknown.

51 **Methods**

52 A male patient presenting with ID, seizures, global developmental delay, hypothyroidism, and
53 primary immunodeficiency was determined to have a novel, heterozygous variant in TLK1
54 (c.1435C>G, p.Q479E) by genome sequencing (GS). Single cell gel electrophoresis, western
55 blot, flow cytometry and RNA-seq were performed in patient-derived lymphoblast cell lines. In
56 silico, biochemical and proteomic analysis were used to determine the functional impact of the
57 p.Q479E variant and previously reported NDD-associated TLK1 variant, p.M566T.

58 **Results**

59 Transcriptome sequencing in patient-derived cells confirmed expression of TLK1 transcripts
60 carrying the p.Q479E variant and revealed alterations in genes involved in class switch
61 recombination and cytokine signaling. Cells expressing the p.Q479E variant exhibited reduced
62 cytokine responses and higher levels of spontaneous DNA damage but not increased sensitivity
63 to radiation or DNA repair defects. The p.Q479E and p.M566T variants impaired kinase activity
64 but did not strongly alter localization or proximal protein interactions.

65 **Conclusion**

66 Our study provides the first functional characterization of TLK1 variants associated with NDDs
67 and suggests potential involvement in central nervous system and immune system

68 development. Our results indicate that, like TLK2 variants, TLK1 variants may impact
69 development in multiple tissues and should be considered in the diagnosis of rare NDDs.

70 **Introduction**

71 The Tousled-like kinases 1 and 2 (TLK1 and TLK2) are conserved serine-threonine kinases that
72 function in numerous cellular processes, including DNA replication, DNA repair, transcription
73 and chromatin maintenance(1). Both TLK1 and TLK2 interact with and regulate the ASF1A and
74 ASF1B histone H3-H4 chaperones(2–7). Depletion of both TLK1 and TLK2, or both ASF1A and
75 ASF1B, led to overlapping cellular phenotypes, including DNA damage, innate immune
76 activation and the induction of the alternative lengthening of telomeres (ALT) pathway(8–10).
77 TLK1 and TLK2 are regulated by the DNA damage response and the phosphorylation of TLK1
78 on its C-terminus by the checkpoint kinase CHK1 inhibits TLK1 activity(11,12). TLK1 also
79 phosphorylates the RAD9 protein, part of the RAD9-RAD1-HUS1 (9-1-1) complex that responds
80 to DNA damage and regulates CHK1 activity, as well as the NEK1 kinase, that is involved in the
81 DNA damage response and ciliogenesis(4,13–19).

82
83 Despite clear associations with fundamental cellular processes and multiple links to the DNA
84 damage response, *Tlk1* deficiency in mice did not result in any overt phenotypes. Notably, both
85 immune system development and fertility were grossly normal, suggesting DNA repair-
86 dependent processes in V(D)J recombination and meiosis were functional(8). Additionally, the
87 deletion of *TLK1* in hundreds of cancer cell lines did not strongly influence cell fitness(20). In
88 contrast, loss of *Tlk2* in mice led to embryonic lethality due to a role in placental development,
89 and *TLK2* is an commonly essential gene in many cancer cell lines, indicating distinct functions
90 or regulation that remain to be fully understood(8,20).

91
92 Variants in *TLK2* have been implicated in Intellectual Developmental Disorder, Autosomal
93 Dominant 57 (MRD57, MIM# 618050), a heterogenous neurodevelopmental disorder (NDD)

94 characterized by intellectual disability (ID), autism spectrum disorder (ASD), microcephaly,
95 additional behavioral problems, growth delay and facial dysmorphism, including
96 blepharophimosis, telecanthus, prominent nasal bridge, broad nasal tip, thin vermilion of the
97 upper lip and upslanting palpebral fissures(21–25). A subset of cases also exhibited
98 gastrointestinal problems, seizures, skeletal malformations and ocular problems. With one
99 exception, all of the disease-associated *TLK2* variants identified to date are heterozygous, and
100 those examined biochemically showed diminished kinase activity, suggesting pathological
101 outcomes are largely due to reduced kinase activity(23,24).

102
103 Activation of TLK2 requires dimerization through its first coiled-coil (CC1), which is also required
104 for its heterodimerization with TLK1(26,27). As TLK1 and TLK2 interact, some of the identified
105 *TLK2* missense variants may exert dominant negative effects on wild type TLK2 and potentially
106 TLK1(28). While >40 *TLK2* variants have been identified in NDD patients, to date, only four *de*
107 *novo* *TLK1* variants have been associated with NDDs (Table 1)(21–25,29). However, no causal
108 links have been established, and the effects of any of the individual variants on protein function
109 have not been investigated.

110
111 Here we report the identification of a male proband who presented with microcephaly, ID,
112 seizures, global developmental delay, cerebral calcifications, feeding difficulties, growth
113 hormone deficiency, hypothyroidism, urticaria and primary immunodeficiency. He had extensive
114 prior genetic testing, including whole exome sequencing (WES), that did not identify a clear
115 genetic cause for his phenotype. Subsequent research exome sequencing (ES) and genome
116 sequencing (GS) through the Rare Genomes Project (RGP) identified heterozygous, *de novo*
117 variants in *TLK1* c.1435C>G (p.Q479E) and *MDM1* c.1197dupT (p.K400Ter).

118

<i>TLK1</i> variant	TLK1 protein	Disease association	Reference
---------------------	--------------	---------------------	-----------

c.74C>T	p.P25L	Intellectual disability	(25)
c.112_113del	p.T38fs	Intellectual disability	ClinVar
c.424G>A	p.R142S	Limb, ear, eye and muscle abnormalities	DECIPHER
c.1101del	p.K367Nfs*	Schizophrenia	(30)
c.1435C>G	p.Q479E	Intellectual disability, microcephaly, immunodeficiency	This study
c.1697T>C	p.M566T	Autism Spectrum Disorder	(29)
c.1796C>G	p.A599G	Congenital heart defect	(31)

119
120 **Table 1:** List of *TLK1* variants reported with links to human disease. Positions are based on
121 [NM_012290.5](#).
122

123 **Materials and Methods**

124 **Genome sequencing (GS), variant calling, and prioritization**

125 GS and data processing for this individual and his parents were performed by the Genomics
126 Platform at the Broad Institute of MIT and Harvard. PCR-free preparation of sample DNA (350
127 ng input at >2 ng/uL) was accomplished using Illumina HiSeq X Ten v2 chemistry. Libraries
128 were sequenced to a mean target coverage of >30X. WGS data was processed through a
129 pipeline based on Picard, using base quality score recalibration and local realignment at known
130 indels. The BWA aligner was used for mapping reads to the human genome build 38. Single
131 Nucleotide Variants (SNVs) and insertions/deletions (indels) were jointly called across all
132 samples using the Genome Analysis Toolkit (GATK) HaplotypeCaller package version 4.0.
133 Default filters were applied to SNV and indel calls using the GATK Variant Quality Score
134 Recalibration (VQSR) approach. Annotation was performed using Variant Effect Predictor
135 (VEP). GATK-SV(32) was used to detect structural variants (SVs), which were annotated with
136 the GATK SVAnnotate tool. Mitochondrial DNA (mtDNA) single nucleotide and small indel
137 variants were called from GS data using the gnomAD-mitochondria pipeline(33) and large
138 mtDNA deletions were called by MitoSAlt(34). ExpansionHunter v5 was used to genotype
139 known disease-associated short tandem repeats (STRs)(35). Lastly, the variant call set was

140 uploaded to seqr for analysis by the RGP team. Variants in *TLK1* (p.Gln479Glu) and *MDM1*
141 (p.Lys400Ter) were submitted to ClinVar (submission ID: SUB13580789).

142

143 **Cell culture and generation of patient cell lines**

144 Peripheral blood mononuclear cells were isolated from whole blood using Histopaque-1077
145 (Sigma-Aldrich) and subsequently immortalized with Epstein-Barr virus transformation (Coriell
146 Institute). Lymphoblastoid cell lines were cultured in RPMI-1640 medium (Corning)
147 supplemented with 15% fetal bovine serum (FBS) (Gibco), 1% penicillin-streptomycin, and 2
148 mM L-glutamine. AD-293 cells (Stratagene) were grown in DMEM supplemented with 10% FBS
149 (Sigma-Aldrich), 50 U/mL penicillin and 50 µg/mL streptomycin (Thermo Fisher Scientific) and
150 authenticated using STR testing (ATCC). All cells were kept at 37°C in a 5% CO₂ incubator.
151 Cells were counted with a Countess cell counter (Invitrogen) and viability was assessed using
152 trypan blue. For any given experiment, only cell cultures with a viability >90% were used. Cells
153 were routinely tested for mycoplasma and found negative (Lonza).

154

155 **Genomic DNA and RNA Purification**

156 Genomic DNA was purified from **lymphoblastoid cell lines** using the Genra Puregene Cell kit
157 (Qiagen) following manufacturer's instructions. Total RNA was extracted from lymphoblastoid
158 cell lines (LCLs) using the SV Total RNA Isolation System (Promega) following manufacturer's
159 instructions. Full methods provided in **online supplemental materials and methods**.

160

161 **PCR amplification and DNA extraction from agarose gels**

162 Genomic DNA was subjected to 35 cycles of PCR amplification using Q5 High-Fidelity DNA
163 Polymerase (New England Biolabs) with primers that allow for the amplification of the region
164 containing the variants of interest (**online supplemental table S1**). PCR products were run in
165 a 2% agarose gel and purified using the Nucleospin Gel and PCR clean-up kit (Macherey-

166 Nagel) following manufacturer's instructions. Full methods provided in **online supplemental**
167 **materials and methods.**

168

169 **Nextera library preparation and sequence analysis for variant calling in PCR products**

170 DNA libraries were prepared using the Nextera XT DNA Library Prep kit (Illumina) following
171 manufacturer's instructions. Sequencing of PCR amplicons was carried out using the MiSeq
172 Nano kit sequencing system (Illumina) with 150 bp paired-end (PE) reads. Cleaned reads were
173 obtained by Trim Galore and FASTQ sequences aligned to the hg38 genome build followed by
174 BCFtools for variant calling and alternate allele frequency of the sequenced genes(36). A filter
175 with quality score ≥ 20 was used to remove variants likely observed purely by chance.

176

177 **RNA sequencing (RNA-seq)**

178 RNA-seq was performed in the CCR Genomics core facility. RNA-seq data processing was
179 performed using the RNA-seq pipelines of the CCBR Pipeliner framework
180 (<https://github.com/CCBR/Pipeliner>). Full analysis methods provided in **online supplemental**
181 **materials and methods.** Data was submitted to GEO: GSE241032.

182

183 ***In silico* prediction and modeling of missense variants**

184 *In silico* prediction of variants was analyzed using seqr (<https://seqr.broadinstitute.org>)(37).
185 Residue conservation was determined using ConSurf (<https://consurf.tau.ac.il>)(38) and the
186 heatmap generated using Prism. The TLK1 kinase domain structure was generated using
187 AlphaFold (<https://alphafold.ebi.ac.uk>) and color modified in PyMol to indicate residues of
188 interest.

189

190 **Comet and cell proliferation assays**

191 Comet assays were performed according to manufacturer's instructions (Trevigen). Proliferation
192 was assessed using the Click-iT Plus EdU Flow Cytometry Assay Kit (Invitrogen) following
193 manufacturer's instructions. Full methods provided in **online supplementary materials and**
194 **methods.**

195

196 **Cloning, site-directed mutagenesis, transfection, streptavidin affinity purification,**
197 **western blotting and kinase assays**

198 Cloning, mutagenesis, transfections, western blotting, streptavidin affinity purification of TLK1
199 from cell lysates and *in vitro* kinase assays were performed as previously described with minor
200 variations(24). Full methods are provided in the online supplemental materials and methods.
201 Primers are provided in **online supplementary table S1**, antibodies are provided in **online**
202 **supplementary table S2** and uncropped westerns including those used for quantification are
203 shown in **online supplementary figure S1**. Westerns and gels used for kinase assays are
204 shown in **online supplementary figure S2**. Proteomic data is available in the PRIDE
205 repository: [PXD019450](https://www.ebi.ac.uk/pride/archive/study/PXD019450).

206

207 **Results**

208 **Identification of a proband with a neurodevelopmental disorder and a *de novo* TLK1**
209 **variant**

210 After an uncomplicated pregnancy, the proband was born with microcephaly noted early in the
211 postnatal period. Between 0-5 months of age, he was admitted to the neonatal intensive care
212 unit (NICU) due to an infection that progressed to respiratory failure. During a several month
213 course in the NICU, he was found to have B- and T-cell deficiency and diagnosed with primary
214 hypothyroidism (TSH 33 uIU/mL, repeat 18.6 uIU/mL). At less than 5 months old, he had a
215 stroke and a generalized seizure and was treated with levetiracetam, after which he was
216 weaned off levetiracetam. Brain MRI revealed symmetric periventricular and subcortical

217 leukoencephalopathy with mild cystic white matter encephalomalacia, ex vacuo
218 ventriculomegaly, thinning of the corpus callosum, and bilateral optic nerve atrophy (**Figure 1A-**
219 **D**).


220 T cells normalized before 5 years of age, but he still has B-cell deficiency and
221 hypogammaglobulinemia (low IgG), treated with weekly subcutaneous immunoglobulin.
222 Enzymatic testing for severe combined immunodeficiency (SCID), including adenosine
223 deaminase (ADA) and purine nucleoside phosphorylase (PNP), was normal (age 0).

224 Between 15 and 20 months, he had a kidney biopsy following episodes of proteinuria and
225 hematuria that was not diagnostic. Between 6 and 10 years old, he was diagnosed with growth
226 hormone deficiency and treated with growth hormone injections.

227 His medical history is also notable for significant global developmental delay, hypotonia, mild
228 outer retinal dystrophy, feeding difficulties, and skin findings including poikiloderma, annular
229 urticaria, and a chronic rash that flares up upon infection. He has used a walker for support from
230 15-20 months of age and has significant speech and language delays, though his receptive
231 abilities are more developed than his expressive language.

232 The proband had thorough clinical genetic testing, all of which came back normal. This included
233 chromosomal microarray and karyotyping, candidate-gene sequencing (*CIAS1*, *RAB27A*,
234 *RECQL4*), targeted mutation analysis (Factor V Leiden p.R506Q, Factor II/prothrombin
235 p.G20210A), mtDNA analysis and nuclear mitochondrial disease panel, and panel testing (SCID
236 panel, Aicardi Goutières panel, Noonan syndrome panel, dyskeratosis congenita panel). Clinical
237 exome sequencing (ES) and subsequent ES reanalysis in 2017 were negative.

238 Research GS done through RGP identified a rare *de novo* frameshift variant in *MDM1*
239 (c.1197dupT; p.Lys400Ter; 12:68315249, hg38) and a rare *de novo* missense variant in *TLK1*
240 (c.1435C>G; p.Gln479Glu; 2:171007045, hg38) further detailed in this report.



241

242 **Figure 1:** T2/FLAIR axial (A, B), sagittal (C), and coronal (D) sections from age 10-15 years
243 shows symmetric periventricular and subcortical leukoencephalopathy with mild cystic white
244 matter encephalomalacia, ex vacuo ventriculomegaly, and thin corpus callosum.


245

246 **Characterization of patient-derived cells expressing the *TLK1* and *MDM1* variants**

247 To further investigate the potential impact of the mutations, PBMCs from the proband and an
248 unaffected female sibling of a similar age, were isolated and transformed with Epstein Barr Virus
249 (EBV) to generate lymphoblastoid cell lines (LCLs). Genomic DNA from expanded LCLs was

250 amplified with specific primers, and sequencing confirmed the presence of both the *TLK1* and
251 *MDM1* variants identified by GS.

252
253 We next performed RNA-seq on each LCL to identify differentially expressed genes (DEGs) and
254 assess the expression levels of the specific variant alleles of both *MDM1* and *TLK1*. Both *TLK1*
255 and *MDM1* were expressed to similar levels in each cell line (**Figure 2A and online**
256 **supplementary table S3**). The allele harboring the *TLK1* variant was transcribed to a similar
257 extent as the wildtype allele (**Figure 2B and online supplementary table S4**), and quantitative
258 western blotting showed total TLK1 protein levels slightly elevated in cells from the proband with
259 the p.Q479E variant compared to the unaffected sibling (**Figure 2C**). In contrast to the *TLK1*
260 variant, the *MDM1* mutant allele was not detectably expressed, likely indicating nonsense-
261 mediated RNA decay (NMD) (**Figure 2B**). However, total MDM1 protein levels appeared similar,
262 consistent with RNA-seq data, suggesting that MDM1 protein levels are unaffected in the LCL
263 line (**Figure 2D**). We next examined the phosphorylation of two reported TLK1 substrates
264 ASF1A and NEK1(6,17). In both cases, no significant difference in phosphorylation of either
265 substrate could be observed between the cell lines (**Figure 2E-F**).



266

267 **Figure 2: *TLK1* and *MDM1* variant alleles and impact on protein levels. A.** Normalized read

268 counts for the indicated genes from RNA-seq of transformed LCLs of the Sibling or Proband.

269 N=2, mean and standard deviation are shown. Full details in **online supplementary table S3**.

270 **B.** Allele specific expression of the indicated genes in the Proband inferred from RNA-seq data.

271 N=2, mean and standard deviation are shown. Full details in **online supplementary table S4**.

272 **C.** Representative blot of protein levels of *TLK1*. Quantification of western blots (N=5) is shown

273 in right panel normalized to Vinculin or Actin. **D.** Representative blot of protein levels of *MDM1*

274 and quantification of western blots (N=4) is shown in right panel normalized to Vinculin or Actin.

275 **E.** Representative blot of *ASF1A* and *ASF1A*-pS166 (*ASF1A*-p) levels and quantification of

276 western blots (N=2) is shown in right panel. **F.** Representative blot *NEK1*-pS141 (P-*NEK1*)

277 levels and quantification of western blots (N=3) is shown in right panel. N represents biological
278 replicates, statistical significance was determined using an unpaired t test with Welch's
279 correction (*P<0.05) in panels C,D.


280

281 **Gene expression differences consistent with immunodeficiency**

282 RNA-seq data was further analyzed to identify DEGs between the LCL cell lines (**Figure 3A**).
283 Ingenuity pathway analysis (IPA) identified Primary Immunodeficiency Signaling (PID) as a top
284 enriched category, consistent with the immunodeficiency of the proband (**Figure 3A-C**). Many of
285 the genes identified are involved in class switch recombination (CSR), and additional DEGs in
286 CSR genes were identified manually, including CD27 and FCRL3 (**Online supplemental table**
287 **S3**). In addition, the STAT3 pathway, Osteoarthritis pathway (OSTEO) and Hepatic fibrosis
288 pathways were among the top 4 significantly altered pathways in the LCLs of the proband
289 compared to the sibling (**Figure 3A-C**). Notably, these pathways included a number of
290 transcriptional regulators, cytokines and other cell surface proteins that influence cell to cell
291 interactions in the immune system.

292

293 Examination of the STAT3 signaling related genes revealed a number of DEGs, including the
294 Interleukin-6 receptor (IL6R) and CSF2RB, which is a component of multiple cytokine receptors.
295 As mutations in STAT3 and IL6R are associated with distinct immunodeficiency syndromes
296 (39), we analyzed STAT3 signaling in cells treated with IL6 and examined the phosphorylation
297 of Tyrosine 705 (Y705) of STAT3, a marker of its activation. While increased levels of pY705-
298 STAT3 were observed in both samples following IL6 treatment, it was markedly reduced in the
299 proband, indicating reduced sensitivity to IL6 (**Figure 3D**). Together, these data indicated that
300 the cells from the proband showed gene expression changes consistent with immunodeficiency
301 and defective CSR and were less responsive to IL6 cytokine stimulation.



302
303 **Figure 3: Gene expression differences identify defects in STAT3 signaling in patient-**
304 **derived cell lines. A.** Volcano plot of RNA-seq data depicting DEGs in the Proband compared
305 to Sibling LCLs. Duplicate samples from each LCL line were analyzed. Full data in **online**

306 **supplemental Table S3.** Genes in each enriched category identified in IPA analysis (B) are
307 shown in the indicated color. Hepatic fibrosis genes overlap with Osteoarthritis and are therefore
308 not shown. **B.** Ingenuity Pathway Analysis (IPA) of RNA-seq data is shown. **C.** Heatmap of
309 individual genes from the indicated enriched pathway are shown. **D.** Analysis of STAT3
310 phosphorylation on Y705 in response to IL6 in LCLs. Quantification of 4 independent
311 experiments is shown below the western blot. STAT3-p (Y705)/STAT3 was normalized to
312 vinculin and samples were normalized to Sibling -IL6. Statistical significance was determined
313 using an unpaired t test with Welch's correction (*P<0.05).

314

315 **Growth defects and increased DNA damage in a patient-derived cell line**


316 To determine the potential impact of the genetic variants and DEGs on cell growth and viability,
317 we compared the growth of the proband- and sibling-derived cell lines by plating the same
318 number of live cells and counting them every 24 hours over 72 hours. Viability at the beginning
319 of the experiment was always >90%. The proband-derived cells showed reduced growth over
320 72 hours, with observable differences after 48 hours (**Figure 4A**). Flow cytometry analysis of
321 EdU-pulsed cultures showed a reduction of cells in S-phase with a compensatory increase in
322 the G1 population (**Figure 4B and 4C**). Both the G2/M and sub-G1 populations were also
323 increased in cells from the proband (Figure 4B and 4C). As this suggested potential activation of
324 cell cycle checkpoints, we examined p53 and p21 levels and found that both were upregulated
325 in the proband compared to the unaffected sibling (**Figure 4D and 4E**).

326

327 As the increased p53/p21 levels and elevated sub-G1 population suggested stress or DNA
328 damage signaling, we used the alkaline comet assay to examine the LCLs for spontaneous
329 DNA damage and to examine DNA repair following exposure to 2 Gy ionizing radiation (IR). The
330 proband-derived cells showed increased tail moment values in the alkaline comet assay in the
331 absence of IR treatment, indicating elevated levels of DNA damage (**Figure 4F and 4G**).

332 However, examination using the neutral comet assay did not reveal evidence of increased DNA
333 strand breaks (**Figure 4H**). Consistent with an absence in DSB repair defects, comets induced
334 by IR treatment were resolved similarly to those in the control cell line, indicating that overall
335 DSB repair was functional, suggesting that spontaneous damage may be ssDNA gaps or base
336 damage (**Figure 4G**).

337



339 **Figure 4: Analysis of cell cycle and DNA damage in patient cell lines. A.** Relative cell
340 growth of the Proband and Sibling LCLs. N=6. **B.** Example of representative flow cytometry data
341 to analyze cell cycle in LCLs. Cells were pulsed with 10 μ M EdU for 1 hour and stained with
342 DAPI for DNA content. **C.** Quantification of cell cycle phases from N=2 independent
343 experiments with 2 biological replicates each. Replicates from same experiment indicated with a
344 triangle or circle. **D.** Western blot analysis of p53 and p21 levels in LCLs. **E.** Quantification of
345 p53 (N=4) and p21 (N=3) levels from biological replicates. **F.** Representative images of alkaline
346 comet assays untreated or treated with the indicated dose of ionizing radiation (IR). **G.** Analysis
347 of tail moment with the indicated treatments and recovery times. Representative of N=2
348 independent experiments. **H.** Analysis of tail moment in neutral comet assays. Representative of
349 N=2 independent experiments. At least 100 comets were analyzed per condition and
350 experiment. Statistical significance was determined using an unpaired t test with Welch's
351 correction (****P<0.0001, ***P<0.001, **P<0.01, *P<0.05).

352






353 ***In silico* and biochemical analysis of the *TLK1* variant**

354 As the *TLK1* variant was the best genetic candidate for the observed phenotypes, we analyzed
355 it with a variety of prediction tools to determine if the variant was potentially damaging to TLK1
356 activity (37). The results were variable, with some prediction tools indicating that the variant was
357 damaging and others indicating it was tolerated (**online supplementary table S5**). Analysis of
358 missense constraint (www.decipher.com) indicated that the kinase domain of TLK1 is highly
359 constrained (**online supplementary figure S3**). We next analyzed the specific conservation of
360 the Q479 residue using ConSurf, including also an additional *TLK1* variant that was previously
361 reported in a patient with ASD, p.M566T (Table 1)(29,38). Both residues are located within the
362 kinase domain of TLK1, with Q479 located in a beta sheet of the N-lobe and M566 in an alpha
363 helix of the C-lobe. Both residues scored as highly conserved, indicating that they could be
364 important for kinase activity (**Figure 5A**).

365

366 To directly determine if kinase activity was affected, the p.Q479E or p.M566T variants were
367 generated in an expression vector using site-directed mutagenesis. N-terminally Strep-FLAG-
368 tagged TLK1-WT, or the two variants, were expressed in AD-293 cells and affinity purified from
369 cell lysates for *in vitro* kinase assays using purified ASF1A as a substrate (**Figure 5B**). A kinase
370 dead mutant of TLK2 (D592V) was used as a negative control for non-specific labeling of the
371 substrate(24). Both the p.Q479E and p.M566T variant proteins showed reduced
372 autophosphorylation activity compared to TLK1-WT and their kinase activity was impaired to
373 similar extent as TLK2-KD compared to TLK1-WT (**Figures 5B-C**). These results indicated that
374 both variants resulted in severely impaired TLK1 kinase activity.

375



377 **Figure 5: Conservation analysis, kinase activity and proximal interactions of NDD**
378 **associated TLK1 variants. A.** ConSurf was used to analyze the level of conservation of the
379 amino acids of human TLK1, with both Q479 and M566 scoring as highly conserved. The
380 predicted structure of the TLK1 kinase domain (AlphaFold) is shown with the location of the two
381 residues highlighted in pink(42,43). **B.** Representative *in vitro* kinase assay of Streptavidin
382 purified TLK1-WT or NDD variants on purified ASF1A. TLK2-KD is used as a negative control.
383 **C.** Quantification of N=4 independent kinase assay experiments. **D.** Western blotting of
384 transfected BioID constructs and biotin labeling imaged with Streptavidin. Ponceau is provided
385 as a transfer control. **E.** Network depiction of the proximal interactors identified with TLK1 with
386 physical interactions indicated by solid lines. Proteins identified on nascent DNA at replication
387 forks by iPOND-MS and proteins in the Simon's Foundation Autism Research Initiative (SFARI)
388 or DECIPHER databases are indicated(44). Full results provided in **online supplementary**
389 **table S6** and additional data in **online supplementary figure S4**.

390

391 **The NDD-associated TLK1 variants do not strongly alter the proximal proteome**

392 We next examined the proximal proteomes of the TLK1 variants using BioID-MS. The BioID
393 enzyme was fused to the N-terminus of the wild type (WT), p.Q479E and p.M566T constructs,
394 and they were expressed by transient transfection in AD293 cells that were pulsed with biotin for
395 24 hours (**Figure 5D**)(40). Cells were harvested and biotinylated proteins purified using
396 Streptavidin beads. Isolated proteins were subjected to mass spectrometry and analyzed using
397 SAINTexpress to identify proteins specifically labeled by TLK1-WT or either variant allele
398 (**online supplementary table S6**)(41). The overall network of proximal interactors identified
399 was similar to that we previously observed for TLK2 (**Figure 5E and online supplementary**
400 **figure S4**)(24). Few strong differences in proximal interactors with either p.Q479E and p.M566T
401 were identified, including with substrates ASF1A and ASF1B, or DYNLL1/LC8, which we
402 previously identified as a robust interactor of TLK2 (**online supplementary figure S4 and table**

403 **S6**) (8) (24). These results indicated that while both TLK1 variants had reduced activity, their
404 proximal interactions were not strongly altered, in contrast to what was observed with several
405 TLK2 NDD variants we previously reported(24).

406

407 **Discussion**

408 In this report we describe a proband with a complex phenotype including developmental delay,
409 intellectual disability, leukoencephalopathy, and primary immunodeficiency. Genetic testing
410 identified potential candidate genes, including *TLK1* and *MDM1*. The *MDM1* variant was not
411 detectable in LCLs, but total *MDM1* expression levels did not appear to be strongly altered at
412 the mRNA or protein level (**Figure 2**). However, we cannot rule out a potential impact of *MDM1*
413 haploinsufficiency in other tissues. In mice, a homozygous truncation mutation of *Mdm1* was
414 linked to retinal degeneration(45). Therefore, the optic nerve atrophy or retinal dystrophy
415 observed in the proband could reflect defects in MDM1 function due to heterozygous expression
416 of the truncated allele or haploinsufficiency in eye development. However, we suggest that
417 *TLK1* is the most likely genetic contributor to the overall phenotype, particularly the
418 neurodevelopmental outcomes.

419

420 While TLK1-deficient mice do not exhibit any obvious developmental phenotypes, ample
421 evidence exists that kinase dead forms of TLK1 may impact the function of TLK1 or TLK2
422 through heterodimerization via the CC1 motif, resulting in a dominant negative effect(26–28).
423 We examined several substrates of TLK1, ASF1A and NEK1, and did not find a clear difference
424 in their phosphorylation in patient-derived cell lines (**Figure 2**). However, cells exhibited
425 significant levels of spontaneous DNA damage and growth defects (**Figure 4**), indicating
426 potential effects on other substrates that we did not analyze in this study. Recent work identified
427 RAD54, a protein involved in homologous recombination of DSBs, as a TLK1 substrate(46).
428 However, the increased DNA damage we observed was not DSBs. TLK1 BioID identified two

429 proteins involved in Mismatch Repair (MMR), MSH3 and POLD1, as proximal interactors
430 (**Figure 5**). The MMR pathway is involved in the repair of some types of base damage, including
431 that caused by elevated reactive oxygen species, and is also required for CSR(47,48). Thus,
432 TLK1 could potentially play an undefined regulatory role in MMR that is compromised by the
433 variant allele.

434
435 Immunodeficiency has not been reported in mouse models of TLK1 or TLK2 deficiency and is
436 therefore hard to directly link to the heterozygous *TLK1* variant identified in this patient based on
437 current knowledge(8). The immunological presentation, as well as the RNA-seq data generated
438 from PBMCs and LCLs, is consistent with defects in lymphocyte maturation, particularly in B-
439 cells, reflecting the proband's status (**Figure 3**). While the proband initially presented with
440 primary immunodeficiency, T-cells recovered, indicating that remaining issues may be the result
441 of impaired B-cell maturation. CSR is a B-cell specific process that is dependent on a number of
442 non-homologous end-joining (NHEJ) pathway genes that largely, but do not completely, overlap
443 with those required for V(D)J recombination(49). A particular feature of CSR is a distinct
444 requirement for 53BP1 and RIF1 that work with a number of proteins to prevent resection and
445 enforce NHEJ(50). Recent work directly linked ASF1 to RIF1-dependent NHEJ DNA repair(51–
446 53). We, and others, have identified RIF1 as a proximal interactor with TLK1 and TLK2 (8,52–
447 54). Thus, defects in TLK1 that influence ASF1 function in this pathway could potentially impact
448 CSR. Further work remains to determine how important TLK-mediated regulation of ASF1 is to
449 RIF1-dependent NHEJ in the context of CSR or if other key repair proteins are regulated by
450 TLK1.

451
452 The STAT3 signaling pathway is important for immune system development and emerged as a
453 clearly enriched pathway in our analysis of RNA-seq data. We demonstrated that LCLs are less
454 responsive to IL6 stimulation, likely due to a reduction in IL6R levels (**Figure 3**). Whether this is

455 a direct result of the TLK1 mutation or reflects the proband's immunodeficient status, we cannot
456 determine for certain. However, it is notable that a number of other signaling pathways are not
457 perturbed, including the phosphorylation of two reported substrates, ASF1A and NEK1 (**Figure**
458 **2**), as well as PKC signaling that has been previously linked with neurodevelopmental disorders
459 (**Supplementary Figure S5**)(55). Thus, we postulate that alterations in the STAT3 pathway
460 could potentially contribute to the immune system phenotypes.

461
462 In a previous study of *TLK2* variants implicated in MRD57, we observed altered proximal
463 interactions and partial mislocalization of TLK2 variant proteins. In contrast, we did not observe
464 that with either *TLK1* variant, as both showed a very similar repertoire of proximal interactors
465 compared to WT. This suggests potential differences in TLK1 and TLK2 regulation that remain
466 to be further explored. Despite this, the proximal interaction profiles of TLK1 and TLK2 were
467 highly similar, further supporting the proposition that they have a large degree of redundancy
468 (**Figure 5**)(8). As *TLK2* mutations clearly impact neurodevelopment, we propose that the
469 p.Q479E variant likely interferes with overall TLK1-TLK2 activity via homo and
470 heterodimerization that impairs chromatin maintenance during brain development. Further
471 analysis of the neurodevelopmental phenotypes of TLK1- and TLK2-deficient mice is therefore
472 warranted.

473
474 In summary, our data strongly indicates that mutations in *TLK1* are likely to be relevant to rare
475 NDDs and should be considered in clinical diagnostics. Further, TLK1, and potentially TLK2,
476 may impact immune system development in certain contexts and additional work is needed to
477 understand their cellular and developmental roles.

478

479 **Data availability statement**

480 Data are available in public, open access repositories GEO (<https://www.ncbi.nlm.nih.gov/geo/>)
481 ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and PRIDE (<https://www.ebi.ac.uk/pride/>),
482 included in the article or uploaded as supplementary information.

483

484 **Ethics approval**

485 The study protocol was approved by the Mass General Brigham Institutional Review Board and
486 informed consent was obtained from the participating family.

487

488 **Acknowledgements**

489 We thank the Stracker lab and L. Deriano for helpful discussions, S. Khurana for antibody
490 optimization, A. De Benedetti for the kind gift of p-NEK1 antibody, D. Zafra and J. Motley for
491 collaboration agreement support, and the IRB Barcelona mass spectrometry core facility and
492 the CCR Genomics facility for technical support. Thank you to the RGP and Broad Institute
493 Center for Mendelian Genomics teams, particularly Melanie O’Leary and Heidi Rehm for project
494 leadership, Ben Weisburd for tandem repeat analysis, Sarah Stenton for mitochondrial genome
495 analysis, and Alba Sanchis-Juan, Harrison Brand, and Michael Talkowski for structural variant
496 analysis.

497

498 **Funding:** M.V-P. was funded by an FPI fellowship from the Ministry of Science, Innovation and
499 Universities (MCIU: BFU2015-68354-P), T.H.S. was funded by the MCIU (PGC2018-095616-B-
500 I00), the 2017 SGR 1089 (AGAUR), FEDER, the Centres of Excellence Severo Ochoa award
501 and the CERCA Programme. M.S.-C. was supported by the IRB Barcelona. T.H.S, M.V-P, J.S.
502 and U.S. were funded by the NIH Intramural Research Program, National Cancer Institute
503 Center for Cancer Research. Sequencing and analysis were provided by the Broad Institute of
504 MIT and Harvard Rare Genomes Project (RGP) and were funded by the National Human

505 Genome Research Institute grants UM1 HG008900 (with additional support from the National
506 Eye Institute, and the National Heart, Lung and Blood Institute), U01 HG0011755, and R01
507 HG009141 and in part by grant number 2020-224274 from the Chan Zuckerberg Initiative DAF,
508 an advised fund of Silicon Valley Community Foundation. V.S.G. is supported by NIH NHGRI
509 T32 (#1T32HG010464).

510 **Competing interests:** none declared.

511
512 **Supplemental Material:**

513 Supplementary materials and methods.

514 **Supplementary Figures**

515 Figure S1: Uncropped western blots.

516 Figure S2: Uncropped western blots and gels from kinase assays and BioID.

517 Figure S3: Decipher analysis of TLK2.

518 Figure S4: BioID-western blot analysis and results comparisons.

519 Figure S5: Western blotting of PKC substrates.

520 **Supplementary Tables**

521 Table S1: Primers used in this study.

522 Table S2: Antibodies used in this study.

523 Table S3: Differentially expressed genes and IPA analysis (excel).

524 Table S4: Analysis of gene specific SNPs in RNA-seq data.

525 Table S5: Seqr analysis of the *TLK1* mutation.

526 Table S6: BioID-MS data of TLK1 and NDD variants (excel).

527

528

529

530

531

532

533

534

535

536 **Bibliography**

537

- 538 1. Segura-Bayona S, Stracker TH. The Tousled-like kinases regulate genome and
539 epigenome stability: implications in development and disease. *Cell Mol Life Sci.* 2019 Jul
540 13;
- 541 2. Silljé HH, Nigg EA. Identification of human Asf1 chromatin assembly factors as substrates
542 of Tousled-like kinases. *Curr Biol.* 2001 Jul 10;11(13):1068–73.
- 543 3. Pilyugin M, Demmers J, Verrijzer CP, Karch F, Moshkin YM. Phosphorylation-mediated
544 control of histone chaperone ASF1 levels by Tousled-like kinases. *PLoS One.* 2009 Dec
545 16;4(12):e8328.
- 546 4. Canfield C, Rains J, De Benedetti A. TLK1B promotes repair of DSBs via its interaction
547 with Rad9 and Asf1. *BMC Mol Biol.* 2009 Dec 20;10:110.
- 548 5. De Benedetti A. Tousled kinase TLK1B mediates chromatin assembly in conjunction with
549 Asf1 regardless of its kinase activity. *BMC Res Notes.* 2010 Mar 11;3:68.
- 550 6. Klimovskaia IM, Young C, Strømme CB, Menard P, Jasencakova Z, Mejlvang J, et al.
551 Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA
552 replication. *Nat Commun.* 2014 Mar 6;5:3394.
- 553 7. Simon B, Lou HJ, Huet-Calderwood C, Shi G, Boggon TJ, Turk BE, et al. Tousled-like
554 kinase 2 targets ASF1 histone chaperones through client mimicry. *Nat Commun.* 2022
555 Feb 8;13(1):749.
- 556 8. Segura-Bayona S, Knobel PA, González-Burón H, Youssef SA, Peña-Blanco A, Coyaud
557 É, et al. Differential requirements for Tousled-like kinases 1 and 2 in mammalian
558 development. *Cell Death Differ.* 2017 Jul 14;24(11):1872–85.
- 559 9. Lee S-B, Segura-Bayona S, Villamor-Payà M, Saredi G, Todd MAM, Attolini CS-O, et al.
560 Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint
561 and PARP inhibitors. *Sci Adv.* 2018 Aug 8;4(8):eaat4985.
- 562 10. Segura-Bayona S, Villamor-Payà M, Attolini CS-O, Koenig LM, Sanchiz-Calvo M, Boulton
563 SJ, et al. Tousled-Like Kinases Suppress Innate Immune Signaling Triggered by
564 Alternative Lengthening of Telomeres. *Cell Rep.* 2020 Aug 4;32(5):107983.
- 565 11. Krause DR, Jonnalagadda JC, Gatei MH, Sillje HHW, Zhou B-B, Nigg EA, et al.
566 Suppression of Tousled-like kinase activity after DNA damage or replication block requires
567 ATM, NBS1 and Chk1. *Oncogene.* 2003 Sep 4;22(38):5927–37.
- 568 12. Groth A, Lukas J, Nigg EA, Silljé HHW, Wernstedt C, Bartek J, et al. Human Tousled like
569 kinases are targeted by an ATM- and Chk1-dependent DNA damage checkpoint. *EMBO*
570 *J.* 2003 Apr 1;22(7):1676–87.
- 571 13. Kelly R, Davey SK. Tousled-like kinase-dependent phosphorylation of Rad9 plays a role in
572 cell cycle progression and G2/M checkpoint exit. *PLoS One.* 2013 Dec 20;8(12):e85859.
- 573 14. Awate S, De Benedetti A. TLK1B mediated phosphorylation of Rad9 regulates its
574 nuclear/cytoplasmic localization and cell cycle checkpoint. *BMC Mol Biol.* 2016 Feb
575 9;17:3.
- 576 15. Sunavala-Dossabhoy G, De Benedetti A. Tousled homolog, TLK1, binds and

- 577 phosphorylates Rad9; TLK1 acts as a molecular chaperone in DNA repair. *DNA Repair*
578 (Amst). 2009 Jan 1;8(1):87–102.
- 579 16. Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. The TLK1-Nek1 axis
580 promotes prostate cancer progression. *Cancer Lett.* 2019 Jul 1;453:131–41.
- 581 17. Singh V, Connelly ZM, Shen X, De Benedetti A. Identification of the proteome complement
582 of human TLK1 reveals it binds and phosphorylates NEK1 regulating its activity. *Cell*
583 *Cycle.* 2017 May 19;16(10):915–26.
- 584 18. Liu S, Ho CK, Ouyang J, Zou L. Nek1 kinase associates with ATR-ATRIP and primes ATR
585 for efficient DNA damage signaling. *Proc Natl Acad Sci USA.* 2013 Feb 5;110(6):2175–80.
- 586 19. Chen Y, Chen C-F, Riley DJ, Chen P-L. Nek1 kinase functions in DNA damage response
587 and checkpoint control through a pathway independent of ATM and ATR. *Cell Cycle.* 2011
588 Feb 15;10(4):655–63.
- 589 20. Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational
590 correction of copy number effect improves specificity of CRISPR-Cas9 essentiality
591 screens in cancer cells. *Nat Genet.* 2017 Dec;49(12):1779–84.
- 592 21. Reijnders MRF, Miller KA, Alvi M, Goos JAC, Lees MM, de Burca A, et al. De Novo and
593 Inherited Loss-of-Function Variants in TLK2: Clinical and Genotype-Phenotype Evaluation
594 of a Distinct Neurodevelopmental Disorder. *Am J Hum Genet.* 2018 Jun 7;102(6):1195–
595 203.
- 596 22. Woods E, Spiller M, Balasubramanian M. Report of two children with global
597 developmental delay in association with de novo TLK2 variant and literature review. *Am J*
598 *Med Genet A.* 2021 Nov 25;
- 599 23. Töpfer A, Oktay Y, Balaraju S, Yilmaz E, Sonmezler E, Yis U, et al. Severe
600 neurodevelopmental disease caused by a homozygous TLK2 variant. *Eur J Hum Genet.*
601 2020 Mar;28(3):383–7.
- 602 24. Pavinato L, Villamor-Payà M, Sanchiz-Calvo M, Andreoli C, Gay M, Vilaseca M, et al.
603 Functional analysis of TLK2 variants and their proximal interactomes implicates impaired
604 kinase activity and chromatin maintenance defects in their pathogenesis. *J Med Genet.*
605 2020 Dec 15;
- 606 25. Lelieveld SH, Reijnders MRF, Pfundt R, Yntema HG, Kamsteeg E-J, de Vries P, et al.
607 Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability.
608 *Nat Neurosci.* 2016 Sep;19(9):1194–6.
- 609 26. Roe JL, Durfee T, Zupan JR, Repetti PP, McLean BG, Zambryski PC. TOSLED is a
610 nuclear serine/threonine protein kinase that requires a coiled-coil region for
611 oligomerization and catalytic activity. *J Biol Chem.* 1997 Feb 28;272(9):5838–45.
- 612 27. Mortuza GB, Hermida D, Pedersen A-K, Segura-Bayona S, López-Méndez B, Redondo P,
613 et al. Molecular basis of Tousled-Like Kinase 2 activation. *Nat Commun.* 2018 Jun
614 28;9(1):2535.
- 615 28. Sunavala-Dossabhoy G, Li Y, Williams B, De Benedetti A. A dominant negative mutant of
616 TLK1 causes chromosome missegregation and aneuploidy in normal breast epithelial
617 cells. *BMC Cell Biol.* 2003 Oct 28;4:16.
- 618 29. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic,
619 transcriptional and chromatin genes disrupted in autism. *Nature.* 2014 Nov
620 13;515(7526):209–15.
- 621 30. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De
622 novo mutations in schizophrenia implicate synaptic networks. *Nature.* 2014 Feb
623 13;506(7487):179–84.
- 624 31. Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, et al. De novo
625 mutations in congenital heart disease with neurodevelopmental and other congenital
626 anomalies. *Science.* 2015 Dec 4;350(6265):1262–6.
- 627 32. Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Francioli LC, et al. A structural

- 628 variation reference for medical and population genetics. *Nature*. 2020 May
629 27;581(7809):444–51.
- 630 33. Laricchia KM, Lake NJ, Watts NA, Shand M, Haessly A, Gauthier L, et al. Mitochondrial
631 DNA variation across 56,434 individuals in gnomAD. *Genome Res*. 2022 Mar;32(3):569–
632 82.
- 633 34. Basu S, Xie X, Uhler JP, Hedberg-Oldfors C, Milenkovic D, Baris OR, et al. Accurate
634 mapping of mitochondrial DNA deletions and duplications using deep sequencing. *PLoS*
635 *Genet*. 2020 Dec 14;16(12):e1009242.
- 636 35. Dolzhenko E, van Vugt JJFA, Shaw RJ, Bekritsky MA, van Blitterswijk M, Narzisi G, et al.
637 Detection of long repeat expansions from PCR-free whole-genome sequence data.
638 *Genome Res*. 2017 Nov;27(11):1895–903.
- 639 36. Danecek P, McCarthy SA. BCFtools/csq: haplotype-aware variant consequences.
640 *Bioinformatics*. 2017 Jul 1;33(13):2037–9.
- 641 37. Pais LS, Snow H, Weisburd B, Zhang S, Baxter SM, DiTroia S, et al. seqr: A web-based
642 analysis and collaboration tool for rare disease genomics. *Hum Mutat*. 2022
643 Jun;43(6):698–707.
- 644 38. Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, et al. ConSurf 2016: an
645 improved methodology to estimate and visualize evolutionary conservation in
646 macromolecules. *Nucleic Acids Res*. 2016 Jul 8;44(W1):W344-50.
- 647 39. Spencer S, Köstel Bal S, Egner W, Lango Allen H, Raza SI, Ma CA, et al. Loss of the
648 interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory
649 responses. *J Exp Med*. 2019 Sep 2;216(9):1986–98.
- 650 40. Kim DI, Jensen SC, Noble KA, Kc B, Roux KH, Motamedchaboki K, et al. An improved
651 smaller biotin ligase for BioID proximity labeling. *Mol Biol Cell*. 2016 Apr 15;27(8):1188–
652 96.
- 653 41. Teo G, Liu G, Zhang J, Nesvizhskii AI, Gingras A-C, Choi H. SAINTexpress:
654 improvements and additional features in Significance Analysis of INTERactome software. *J*
655 *Proteomics*. 2014 Apr 4;100:37–43.
- 656 42. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold
657 Protein Structure Database: massively expanding the structural coverage of protein-
658 sequence space with high-accuracy models. *Nucleic Acids Res*. 2022 Jan
659 7;50(D1):D439–44.
- 660 43. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate
661 protein structure prediction with AlphaFold. *Nature*. 2021 Aug;596(7873):583–9.
- 662 44. Wessel SR, Mohni KN, Luzwick JW, Dungrawala H, Cortez D. Functional analysis of the
663 replication fork proteome identifies BET proteins as PCNA regulators. *Cell Rep*. 2019 Sep
664 24;28(13):3497–3509.e4.
- 665 45. Chang B, Mandal MNA, Chavali VRM, Hawes NL, Khan NW, Hurd RE, et al. Age-related
666 retinal degeneration (*arrd2*) in a novel mouse model due to a nonsense mutation in the
667 *Mdm1* gene. *Hum Mol Genet*. 2008 Dec 15;17(24):3929–41.
- 668 46. Ghosh I, Kwon Y, Shabestari AB, Chikhale R, Chen J, Wiese C, et al. TLK1-mediated
669 RAD54 phosphorylation spatio-temporally regulates Homologous Recombination Repair.
670 *Nucleic Acids Res*. 2023 Jul 13;
- 671 47. Schrader CE, Edelman W, Kucherlapati R, Stavnezer J. Reduced isotype switching in
672 splenic B cells from mice deficient in mismatch repair enzymes. *J Exp Med*. 1999 Aug
673 2;190(3):323–30.
- 674 48. Ehrenstein MR, Neuberger MS. Deficiency in *Msh2* affects the efficiency and local
675 sequence specificity of immunoglobulin class-switch recombination: parallels with somatic
676 hypermutation. *EMBO J*. 1999 Jun 15;18(12):3484–90.
- 677 49. Saha T, Sundaravinayagam D, Di Virgilio M. Charting a DNA repair roadmap for
678 immunoglobulin class switch recombination. *Trends Biochem Sci*. 2021 Mar;46(3):184–99.

- 679 50. Zimmermann M, de Lange T. 53BP1: pro choice in DNA repair. Trends Cell Biol. 2014
680 Feb;24(2):108–17.
- 681 51. Lee KY, Im J-S, Shibata E, Dutta A. ASF1a Promotes Non-homologous End Joining
682 Repair by Facilitating Phosphorylation of MDC1 by ATM at Double-Strand Breaks. Mol
683 Cell. 2017 Oct 5;68(1):61–75.e5.
- 684 52. Tang M, Chen Z, Wang C, Feng X, Lee N, Huang M, et al. Histone chaperone ASF1 acts
685 with RIF1 to promote DNA end-joining in BRCA1-deficient cells. J Biol Chem. 2022 Apr
686 23;101979.
- 687 53. Feng S, Ma S, Li K, Gao S, Ning S, Shang J, et al. RIF1-ASF1-mediated high-order
688 chromatin structure safeguards genome integrity. Nat Commun. 2022 Feb 17;13(1):957.
- 689 54. Sukackaite R, Cornacchia D, Jensen MR, Mas PJ, Blackledge M, Enverald E, et al.
690 Mouse Rif1 is a regulatory subunit of protein phosphatase 1 (PP1). Sci Rep. 2017 May
691 18;7(1):2119.
- 692 55. Callender JA, Newton AC. Conventional protein kinase C in the brain: 40 years later.
693 Neuronal Signal. 2017 Apr 10;1(2):NS20160005.
694